-
Mashup Score: 9Nivolumab with CAR T-cell therapy in progressive DLBCL: final analysis of a phase II study - 2 day(s) ago
Here we summarize results from a phase II trial investigating the addition of nivolumab to CAR T-cell therapy in patients with progressive DLBCL, presented by Amit at EBMT 2024.
Source: lymphomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 8
Here, we summarize an analysis of CD19-targeting CAR T-cell therapy in patients with PCNSL or SCNSL, presented by Ossami Saidy during the 50th Annual Meeting of the EBMT.
Source: lymphomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Camrelizumab plus GEMOX as salvage therapy for R/R cHL: Results from a phase II trial - 10 day(s) ago
Here, we summarize results from a phase II trial assessing the safety and efficacy of camrelizumab in combination with GEMOX followed by auto-HSCT in patients with R/R cHL.
Source: lymphomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 18What is the rationale for monitoring secondary malignancies after BCMA and CD19 CAR T cell therapy - 14 day(s) ago
The Lymphoma Hub and Multiple Myeloma Hub were pleased to speak to Anna Sureda, Catalan Institute of Oncology, Barcelona, ES. We asked, What is the rationale…
Source: www.youtube.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 14Lisocabtagene maraleucel as a second-line treatment for R/R LBCL: PROs from the PILOT study - 17 day(s) ago
Here, we summarize a health-related quality of life and patient-reported outcomes analysis from the phase II PILOT trial, published by Gordon et al. in Haematologica.
Source: lymphomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Correlation between MRD at the end of induction and EFS in pediatric T-cell lymphoblastic lymphoma - 22 day(s) ago
Here, we summarize a subgroup analysis of the Children’s Oncology Group AALL1231 trial investigating the correlation between MRD at the end of induction and event-free survival in pediatric patients with T-cell lymphoblastic lymphoma published by Hayashi et al.1 in Blood.
Source: lymphomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 10Waldenström’s macroglobulinemia | Lymphoma Hub - 23 day(s) ago
Online lymphoma resource for healthcare professionals, providing information, news & support relating to lymphoma, Hodgkin & non Hodgkin disease
Source: lymphomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6STARGLO trial of glofitamab: primary endpoint met in R/R DLBCL - 24 day(s) ago
Results obtained from the phase III STARGLO trial showed that glofitamab met its primary endpoint of overall response in patients with R/R DLBCL who received at least one prior line of therapy.
Source: lymphomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6
During the 6th European CAR T-Cell Meeting, the Lymphoma Hub was pleased to speak to the president of EBMT, Anna Sureda, Catalan Institute of Oncology, Barcelona, ES.
Source: lymphomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 13Venetoclax monotherapy for patients with R/R CLL: Results from the phase III VENICE-1 trial - 1 month(s) ago
Here we summarize the results from the VENICE-1 trial evaluating venetoclax monotherapy in patients with R/R CLL, published by Kater et al.1 in Lancet Oncology.
Source: lymphomahub.comCategories: General Medicine News, Onc News and JournalsTweet
Is the addition of nivolumab to anti-CD19 CAR T-cell therapy well tolerated and effective in patients with progressive DLBCL? Read our summary of results from a phase II trial here: https://t.co/LiMdbVSzCT #lymsm #lymphoma #EBMT2024 https://t.co/r3Yjd52kWO